Medidata Solutions (MDSO) Price Target Lowered to $79.00 at Morgan Stanley
Several other equities research analysts have also commented on the stock. TheStreet lowered shares of Medidata Solutions from a b rating to a c+ rating in a report on Thursday, December 14th. Zacks Investment Research lowered shares of Medidata Solutions from a hold rating to a sell rating in a report on Wednesday, December 27th. Wells Fargo & Co reduced their price target on shares of Medidata Solutions from $83.00 to $80.00 and set a market perform rating for the company in a report on Friday, October 27th. SunTrust Banks restated a buy rating and issued a $92.00 price target on shares of Medidata Solutions in a report on Friday, October 27th. Finally, Deutsche Bank started coverage on shares of Medidata Solutions in a report on Friday, December 8th. They issued a buy rating and a $78.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. Medidata Solutions presently has a consensus rating of Buy and an average price target of $83.00.
Shares of Medidata Solutions (NASDAQ MDSO) opened at $62.48 on Friday. Medidata Solutions has a twelve month low of $54.36 and a twelve month high of $85.92. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.50 and a quick ratio of 3.37. The company has a market cap of $3,807.70, a PE ratio of 84.43, a PEG ratio of 3.49 and a beta of 1.58.
In other news, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $65.40, for a total value of $130,800.00. Following the transaction, the chief financial officer now owns 91,775 shares of the company’s stock, valued at approximately $6,002,085. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael Pray sold 5,944 shares of Medidata Solutions stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $70.47, for a total transaction of $418,873.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,010 shares of company stock worth $1,962,206. Insiders own 5.80% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Fortaleza Asset Management Inc. purchased a new stake in Medidata Solutions during the 3rd quarter worth approximately $155,000. Polen Capital Management LLC purchased a new stake in Medidata Solutions during the 3rd quarter worth approximately $205,000. Cubist Systematic Strategies LLC purchased a new stake in Medidata Solutions during the 2nd quarter worth approximately $227,000. Hanseatic Management Services Inc. grew its position in Medidata Solutions by 14,915.0% during the 3rd quarter. Hanseatic Management Services Inc. now owns 3,003 shares of the company’s stock worth $234,000 after purchasing an additional 2,983 shares during the last quarter. Finally, Legato Capital Management LLC purchased a new stake in Medidata Solutions during the 3rd quarter worth approximately $248,000. 97.52% of the stock is currently owned by institutional investors.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.